Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5800573 | 0.82 | HTT (0.59) | HTTSMN1; SMN2PKMCYP2C9CYP2C19 | |
| SCHEMBL28088453 | 0.81 | — | — | |
| SCHEMBL21162612 | 0.79 | HTT (0.52) | HTTSMN1; SMN2PKMCYP2C9CYP2C19 | |
| SCHEMBL675834 | 0.78 | POLB (0.68) | HTTSMN1; SMN2PKMCYP2C9CYP2C19 | |
| SCHEMBL6242198 | 0.78 | HTT (0.55) | HTTSMN1; SMN2PKMCYP2C9CYP2C19 | |
| SCHEMBL24254616 | 0.78 | HTT (0.55) | HTTSMN1; SMN2PKMCYP2C9CYP2C19 | |
| SCHEMBL17325765 | 0.78 | HTT (0.55) | HTTSMN1; SMN2PKMCYP2C9CYP2C19 | |
| SCHEMBL9459556 | 0.78 | HTT (0.55) | HTTSMN1; SMN2PKMCYP2C9CYP2C19 | |
| SCHEMBL5117284 | 0.78 | HTT (0.55) | HTTSMN1; SMN2PKMCYP2C9CYP2C19 | |
| SCHEMBL1056413 | 0.78 | HTT (0.55) | HTTSMN1; SMN2PKMCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11608320-B2 | Oxazolidinone hydroxamic acid derivatives | KUWAIT UNIVERSITY (KW) | 2023-03-21 | — | — | US | disclosed |
| US-20210238151-A1 | OXAZOLIDINONE HYDROXAMIC ACID DERIVATIVES | KUWAIT UNIVERSITY (KW) | 2021-08-05 | — | — | US | disclosed |
| EP-2243628-B1 | Method for making lithographic printing plates | AGFA GRAPHICS NV (BE) | 2012-12-05 | — | — | EP | disclosed |
| US-20120034565-A1 | Lithographic printing plate precursor | AGFA GRAPHICS NV (BE) | 2012-02-09 | — | — | US | disclosed |
| US-20120034565-A1 | Lithographic printing plate precursor | AGFA GRAPHICS NV (BE) | 2012-02-09 | — | — | US | disclosed |
| US-4618692-A | ANTITUMOR AGENTS | ASTA-WERKE AKTIENGESELLSCHAFT (DE) | 1986-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238151-A1 | OXAZOLIDINONE HYDROXAMIC ACID DERIVATIVES | ALOX5, ALOX15, ALOX15B | HTT 3582/4885SMN1; SMN2 4316/4885PKM 2120/4885 |
| US-11608320-B2 | Oxazolidinone hydroxamic acid derivatives | ALOX5, ALOX15, ALOX15B | HTT 3530/4885SMN1; SMN2 4313/4885PKM 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.